摘要
慢性阻塞性肺疾病(慢阻肺)急性加重是慢阻肺管理过程中的重要事件,反复急性加重可以降低患者的生活质量,增加住院率和再住院率,加速疾病进展。目前在慢阻肺急性加重的治疗中还存在用药人群、种类、剂型、剂量、给药途径、疗程、撤停等多个方面使用不规范的情况,因此带来的糖皮质激素副反应也较多。慢阻肺急性加重正确使用糖皮质激素可以缩短患者康复时间、改善肺功能和低氧血症。文章对目前糖皮质激素治疗慢阻肺急性加重现状、近些年慢阻肺全球防治策略及急性加重专家共识进行解读,并从循证医学角度探讨糖皮质激素在慢阻肺急性加重治疗中的地位。
Exacerbations of chronic obstructive pulmonary disease （COPD） are important events in the management of COPD because they negatively impact health status, rates of hospitalization and readmission, and disease progression. However, currently, inappropriate and irrational use of glucocorticoids is quite common in the process of the treatment of acute exacerbation of COPD. For example, there are problems in the drug population, type, dosage form, dosage, drug delivery pathwa）5 course of treatment, withdrawal, etc., which lead to a series of side effects. Proper use of glucocorticoids can improve lung function （FEV1）, oxygenation and shorten recovery time. ~his article reviews the current use of glucocorticoid in treatment of AECOPD, outlines the recent global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease and the expert consensus of acute exacerbation, and explores the role ofglucocorticoid in the treatment ofAECOPD ibased on evidence-based medicine.
作者
孙婉璐
陈亚红
SUN Wan-lu;CHEN Ya-hong.(Department of Respiratory and Critical Care Medicinej Peking University Third Hospital, Beijing 100191j China)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2018年第5期446-450,共5页
Chinese Journal of Practical Internal Medicine
基金
国家重点研发计划(2016YFC1304301)
关键词
慢性阻塞性肺疾病
急性加重
糖皮质激素
治疗现状
chronic obstructive pulmonary disease
acute exacerbation
glucocorticoid
treatment status
